Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26807| Title: | Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. | Austin Authors: | Evens, Andrew M;Connors, Joseph M;Younes, Anas;Ansell, Stephen M;Kim, Won Seog;Radford, John;Feldman, Tatyana;Tuscano, Joseph;Savage, Kerry J;Oki, Yasuhiro;Grigg, Andrew P ;Pocock, Christopher;Dlugosz-Danecka, Monika;Fenton, Keenan;Forero-Torres, Andres;Liu, Rachael;Jolin, Hina;Gautam, Ashish;Gallamini, Andrea | Affiliation: | Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.. BC Cancer Centre for Lymphoid Cancer and Department of Medical Oncology, Vancouver.. Memorial Sloan Kettering Cancer Center, NY.. Mayo Clinic, Rochester, NY.. Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul.. University of Manchester and the Christie NHS Foundation Trust Manchester Academic Health Science Centre, Manchester.. John Theurer Cancer Center, NJ.. UC Davis Cancer Center, Sacramento, CA.. BC Cancer Centre for Lymphoid Cancer and Department of Medical Oncology, Vancouver.. Genentech, South San Francisco, CA.. Olivia Newton-John Cancer Wellness and Research Centre Haematology, East Kent Hospitals, Canterbury.. Maria Sklodowska-Curie National Research Institute of Oncology, Krakow.. Seagen Inc., Bothell, WA.. Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.. Research and Innovation Department, A Lacassagne Cancer Centre, Nice.. |
Issue Date: | 2022 | Date: | 2021 | Publication information: | Haematologica 2022; 107(5): 1086-1094 | Abstract: | Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma (cHL). We report results for older patients with cHL treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival (PFS) per independent review facility (IRF) for older versus younger patients (aged ≥60 versus. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/26807 | DOI: | 10.3324/haematol.2021.278438 | Journal: | Haematologica | PubMed URL: | 34162178 | Type: | Journal Article | Subjects: | Hodgkin lymphoma cancer |
| Appears in Collections: | Journal articles |
Show full item record
Page view(s)
26
checked on Dec 18, 2024
Download(s)
76
checked on Dec 18, 2024
Google ScholarTM
Check
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.